- General Chemistry I (CHEM 121)
- General Chemistry I Lab (CHEM 121 L)
- General Chemistry II (CHEM 122)
- General Chemistry II Lab (CHEM 122 L)
- The Drug Trade (First Year Experience Course, FYEC 136)
- Introduction to Research (CHEM 325)
- Medicinal Chemistry (CHEM 402)
- Biochemistry I (CHEM 407)
- Biochemistry I Lab (CHEM 407 L)
- Biochemistry II Lecture and lab (CHEM 408)
- Senior Seminar (CHEM 415)
- Drugs and the Body (CHEM 117)
- Organic Chemistry I (CHEM 221)
- Organic Chemistry II (CHEM 222)
- Introduction to Laboratory Research (CHEM 340)
- Media Myths, Science Facts (First Year Experience Course)
The Synthesis of Organic Molecules to Control Protein Conformation and Function
I am interested in preventing Dengue Virus infections by controlling the conformation and function of the Dengue envelope glycoprotein with small organic molecules. The Dengue Virus is one of approximately 70 flaviviruses which have been identified. Half of these flaviviruses are capable of causing disease in humans. From a public health standpoint, the most important of these viruses include Dengue, West Nile, yellow fever, Japanese encephalitis, and tick-borne encephalitis. Vaccines have been developed for yellow fever, Japanese encephalitis, and tick-borne encephalitis; however, there is currently no known treatment or vaccine for dengue and West Nile viruses.
Both the dengue and West Nile viruses are transmitted to humans through the bite of an infected mosquito. Dengue virus has four antigenically distinct virus serotypes that cause dengue fever, dengue hemmorhagic fever (DHF), and dengue hemmorhagic shock syndrome (DHSS). The symptoms of dengue fever may persist for up to ten days and include a sudden high fever, joint and muscle pain, headaches, nausea, and a mild rash. The symptoms of DHF and DHSS are more severe and are characterized by capillary frailty, potential hemorrhage, and collapse of the cardiovascular system. The dengue virus is endemic in more than 100 countries in Africa, South America, the Eastern Mediterranean, Southeast Asia, and the Western Pacific, while in the 1970s, dengue fever was found in only nine countries. The World Health Organization estimates that up to two-fifths of the world's population (2.5 billion people) are at risk of acquiring the virus. There are 50 million infections per year, and at least 500,000 hospitalizations due to dengue hemmorhagic fever. According to the World Health Organization, the fatality rate is usually 2.5%; however, rates of up to 20% have been reported during some epidemics.
The positive-stranded RNA genome of the dengue virus is packaged in a lipid bilayer with three structural proteins: the core nucleocapsid protein (C), the membrane protein (M) and the envelope glycoprotein (E). The envelope protein is responsible for mediating both receptor binding and fusion with the host cell. The protein is organized into three domains and is found as a metastable head-to-tail dimer that lies flat on the surface of the virus. When the virus is exposed to the low pH (6.0) environment of the endosome after receptor-mediated endocytosis, an irreversible conformational change is initiated that reorganizes the envelope protein into a more stable trimeric species and exposes the fusion peptide.
Nutraceuticals for Drug Discovery
Nutraceuticals are biologically active organic compounds which have disease-preventing or medicinal properties and are found naturally in plants. These compounds have also been referred to as phytochemicals or functional foods. The use of these natural compounds to fight diseases can be traced back to ancient oriental herbal medicine. The drug discovery process is lengthy and it usually takes between 10-15 years for a new drug to come to market. The time this process takes can be drastically reduced if a compound found in a common plant with known toxicity data is found to have nutraceutical properties. This is a particularly attractive option in the case of orphan diseases (where pharmaceutical companies can't recuperate discovery costs) or diseases like the Dengue virus which primarily affect third world countries (where people can't afford expensive drugs).
Green, N. S.; Foss, T. Kelly, J. W. Is Soy Mother Nature's Miracle Worker? Genistein as an Effective Inhibitor of Transthyretin Amyloidosis. Proc. Natl. Acad. Sci. USA. 2005, 102, 14545-14550.
Kelly, J. W.; Green, N. S. Genistein Inhibibition of Transthyretin Amyloidosis."U.S. Patent Application 11/504,134, 2005. International patent application September 2006.
Johnson, S. J.; Wiseman, R. L; Sekijima, Y; Green, N. S.; Adamski-Werner, S. L.; Kelly, J. W. Native State Kinetic Stabilization as a Strategy to Ameliorate Protein Misfolding Diseases: A Focus on the Transthyretin Amyloidoses. Acc. Chem. Res. 2005, 38, 911-921.
Wiseman, R. L.; Green, N. S.; Kelly, J. W. Kinetic Stabilization of an Oligomeric Protein under Physiological Conditions Demonstrated by a Lack of Subunit Exchange: Implications for Transthyretin Amyloidosis Biochemistry 2005, 44, 9265-9274.
Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Synthesis and Characterization of Potent Bivalent Inhibitors of Amyloidosis that Bind Prior to Transthyretin Tetramerization. J. Am. Chem. Soc. 2003, 13404-13414.
Green, N. S.; Reisler, E.; Houk, K. N. Quantitative Evaluation of the Lengths of Homobifunctional Protein Cross-linking Reagents Used as Molecular Rulers. Protein Science 2001, 10, 1293-1304.
Behnam, S. M.; Behnam, S. E.; Ando, K.; Green, N. S.; Houk, K. N. Stereoelectronic, Steric, and Torsional Effects on the Rates of Enolization of Ketones. J. Org. Chem. 2000, 65, 8970-8978.
Green, N. S.; Miller, M. M.; Houk, K. N. Evaluation of Isoprenoid Conformation in Solution and in the Active Site of Protein-Farnesyl Transferase Using Carbon-13 Labeling in Conjunction with Solution- and Solid-State NMR. Chemtracts 2000, 13, 749-756.
Green, N. S.; Houk K. N. Structures of Enzymes involved in Terpenoid Biosynthesis. Chemtracts 2000, 13, 844-852.
Ando, K.; Green, N. S.; Li, Y.; Houk, K. N. Torsional and Steric Effects Control the Stereoselectivities of Alkylations of Pyrrolidinone Enolates. J. Am. Chem. Soc. 1999, 121, 5334-5335.
Green, N. S.; Houk K. N. Structures of Enzymes involved in Terpenoid Biosynthesis. Chemtracts 1998, 11, 537-545.
Leibrand, C.; Green, N.S. “Investigating the Use of Small Molecule Ligands to Stabilize the West Nile Virus at Low pH” American Chemical Society 243rd National Meeting, San Diego, CA March 2012.
Steiner, N.; Green, N.S. “Small molecules capable of stabilizing the West Nile Virus Envelope Protein at low pH.” American Chemical Society 241st National Meeting, Anaheim, CA. March 2011.
Potter, K; Green, N.S. “The Synthesis of Heterocyclic Inhibitors of the Dengue Virus NS3 Protease” American Chemical Society 241st National Meeting, Anaheim, CA. March 2011.
Green, N.S. “Drugs! An Exciting Laboratory Science Course for Non-majors” accepted to American Chemical Society 239th National Meeting, San Francisco, CA. March 2010.
Steiner, N.; Cully, R. S. IV; Green, N.S. “Stabilization of the West Nile Virus Envelope Glycoprotein at Low pH” American Chemical Society 239th National Meeting, San Francisco, CA. March 2010.
Cully, R. S. IV; Green, N. S. “Stabilization of the West Nile Virus Envelope Glycoprotein at Low pH” The American Chemical Society Section Meeting, University of Virginia, April 18, 2008.
Green, N. S. “Teaching Medicinal Chemistry at a Small Liberal Arts College” American Chemical Society 232nd National Meeting, San Francisco, CA. September 12, 2006, COMP 187 (Invited talk).
Green, N.S. “Antiviral Compounds for the Treatment of Dengue Virus” Faculty Research Exchange Evenings (FREE) March 7, 2007 (invited talk).
Green, N. S. “Crossing Boundaries: From Hartree Fock-Up to Protein Chemist” University of California, Los Angeles Chemistry and Biology Interface Symposium, Los Angeles, CA. July 21, 2006. (Invited talk)
Green, N. S. "Purification of Transthyretin: An Experiment for Project-based Biochemistry Laboratories." American Chemical Society 231st National Meeting, Atlanta, GA. March 26, 2006, CHED 112.
Shaner, T. V.; Green, N. S. "Stabilization of the Envelope Protein in Dengue Virus." American Chemical Society 231st National Meeting, Atlanta, GA. March 27, 2006, CHED 784.
Green, N. S.; Foss, T.; Kelly, J. W. “ Genistein, a Natural Product from Soy, is a Potent Inhibitor of Transthyretin Amyloidosis” American Chemical Society 229th National Meeting, San Diego, CA March 13, 2005, MEDI-197.
Green, N. S. “What do Morphine, Computers, Alzheimer’s Disease, and the Dengue Virus Have in Common?” Shapirio Undergraduate Research Fellowship Luncheon July 5, 2005 (invited talk)
Green, N. S.; Houk, K. N. “The Design and Synthesis of Novel Gated Host-Guest Systems.” American Chemical Society 219th National Meeting, San Francisco, CA. March 26, 2000, ORGN 080.
Student Research Projects
Cyrstal Leibrand – SURF 2011, Fall 2011 “Investigating the Use of Small Molecule Ligands in Stabilizing the West Nile Virus Glycoprotein at Low pH”
Nathan Steiner – Fall 09, Spring 2010, SURF 2010, Fall 2010, Spring 2011 “Stabilization of the West Nile Virus Envelope Glycoprotein at Low pH.”
Kimmy Potter – SURF 2010, Fall 2010, Spring 2011 “Synthesis of Heterocyclic Inhibitors of the Dengue Virus NS3 Protease.
Katie Daisey – SURF 2010 Synthesis of inhibitors for Dengue Virus NS3 protease.
Vince Arnone – Fall 2010 Synthesis of fluorescent probes for byrostatins.
Jessica Armstrong – Fall 2010 Screening of nutraceuticals for inhibition of the West Nile virus NS3 Protease.
Crystal Leibrand – Fall 2010. "Synthesis of Disubstituted Urea Compounds for the Inhibition of the Dengue Virus NS3 Protease"
Casey Sheck, SURF 07 “Screening Nutraceuticals for Inhibitors of the Hepatitis C virus NS3 Protease”
Casey Sheck, Spring 09 “Determining the anti-oxidant effect of Different Wines”
Maria Summers, SURF 07, Spring 09 “The Search for West Nile Virus Inhibitors Using Nutraceutical Compounds”
Nelia Kranitzky, SURF 2006, Fall 2006, Spring 2007 “Synthesis of Benzimadazole, Benzothiazole, and Benzotriazole Diarginine Mimics for the Inhibition of the Dengue Virus NS3 Protease”
Perry Kennedy, Senior Thesis Project "Impeding Dengue Virus Activity through the Selection of Plant Extract Inhibitors for the Viral NS3 Protease"
Robert Culley IV, SURF 2005, Spring 2006, SURF 2006, SURF 2007, Senior Thesis Project "Development of a New Gel Filtration Assay to Probe Small Molecule Conformational Control of the Dengue Virus Envelope Glycoprotein."
Ashley A. Ford, SURF 2005 "Synthesis of Heterocyclic Alpha Amino Acid Arginine Mimics as Potential Inhibitors of the Dengue Virus."
Kerisa Harriott, SURF 2005, Spring 2006, Spring 2007 "Synthesis of Disubstituted Urea Compounds for the Inhibition of the Dengue Virus NS3 Protease"
Ted Shaner, SURF 2005, Fall 2005, Spring 2006 "Stabilization of the Envelope Protein in Dengue Fever."
Diana Wright, Spring 2006 "Fluorescent Studies on Transthyretin."
Nicki Kennedy – Spring 2005 “Preliminary Studies on the Expression of the Dengue Virus Envelope Glycoprotein in E. Coli.”
Ellen Sakell, January 2005, Spring 2005 "Solid Phase Peptide Synthesis of a Chromogenic Peptide Substrate for the Dengue Virus NS3 Protease."
Other Interesting Links
Links of Personal Interest
My Dog Abby